Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

Abstract

Multiple myeloma (MM) is a plasma cell malignancy preliminary localized in the bone marrow and characterized by its capacity to disseminate. IL-6 and IGF-1 have been shown to mediate proliferative and anti-apoptotic signals in plasmocytes. However, in primary plasma-cell leukemia (PCL) and in end-stage aggressive extramedullar disease, the cytokine requirement for both effects may be not mandatory. This suggests that constitutive activation of signaling pathways occurs. One of the signaling pathways whose deregulation may play an oncogenic role in MM is the phosphatidylinositol 3-kinase (PI 3-K) pathway. In human growth factor-independent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70S6K) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation. In both cell lines, constitutive activation of the PI 3-K/Akt/FKHRL-1, mTOR/P70S6K and MAPK pathways was detected. LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70S6K but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent. IGF-1 but not IL-6 increased phosphorylation of Akt, FKHRL-1 and P70S6K. Purified plasmocytes from four patients with MM and two patients with primary PCL were studied. In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70S6K was present, inhibited by LY294002 and enhanced by IGF-1. In these patients with constitutive Akt activation, normal PTEN expression was detected. PI 3-K inhibition induced caspase-dependent apoptosis as confirmed by inhibition with the large spectrum caspase inhibitor Z-VAD-FMK and cleavage of pro-caspase-3. Both cell lines spontaneously expressed Skp2 and cyclin D1 proteins at high levels but no p27Kip1 protein. In the presence of LY294002, cell-cycle arrest in G0/G1 was observed, p27Kip1 protein expression was up-regulated whereas the expression of both Skp2 and cyclin D1 dramatically diminished. PI 3-K-dependent GSK-3α/β constitutive phosphorylation was also detected in OPM2 cells that may contribute to high cyclin D1 expression. Overall, our results suggest that PI 3-K has a major role in the control of proliferation and apoptosis of growth factor-independent MM cell lines. Most of the biological effects of PI 3-K activation in these cell lines may be mediated by the opposite modulation of p27Kip1 and Skp2 protein expression. Moreover, constitutive activation of this pathway is a frequent event in the biology of MM in vivo and may be more frequently observed in PCL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J . 1998 Curr. Biol. 8: 69–81

  • Aoki M, Blazek E, Vogt PK . 2001 Proc. Natl. Acad. Sci. USA 98: 136–141

  • Barata JT, Cardoso AA, Nadler LM, Boussiotis VA . 2001 Blood 98: 1524–1531

  • Brennan P, Babbage JW, Thomas G, Cantrell D . 1999 Mol. Cell. Biol. 19: 4729–4738

  • Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME . 1999 Cell 96: 857–868

  • Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC . 1998 Science 282: 1318–1321

  • Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R . 1999 Immunity 10: 105–115

  • Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK . 1997 Science 276: 1848–1850

  • Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR . 1996 Proc. Natl. Acad. Sci. USA 93: 3636–3641

  • Datta SR, Brunet A, Greenberg ME . 1999 Genes Dev. 13: 2905–2927

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME . 1997 Cell 91: 231–241

  • De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . 2000 Br. J. Haematol. 109: 823–882

  • Diehl JA, Cheng M, Roussel MF, Sherr CJ . 1998 Genes Dev. 12: 3499–3511

  • Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ . 2000a Mol. Cell. Biol. 20: 9138–9148

  • Dijkers PF, Medemadagger RH, Lammers JW, Koenderman L, Coffer PJ . 2000b Curr. Biol. 10: 1201–1204

  • Feng LX, Ravindranath N, Dym M . 2000 J. Biol. Chem. 275: 25572–25576

  • Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B . 2000 Br. J. Haematol. 111: 626–634

  • Freund GG, Kulas DT, Mooney RA . 1993 J. Immunol. 151: 1811–1820

  • Ge NL, Rudikoff S . 2000a Oncogene 19: 4091–4095

  • Ge NL, Rudikoff S . 2000b Blood 96: 2856–2861

  • Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ . 2001 Proc. Natl. Acad. Sci. USA 98: 9666–9670

  • Hideshima T, Nakamura N, Chauhan D, Anderson KC . 2001 Oncogene 20: 5991–6000

  • Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ . 1999 Cancer Res. 59: 886–894

  • Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A . 2001 Blood 98: 2853–2855

  • Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS, Li W . 2000 Blood 96: 3560–3568

  • Kennedy SG, Kandel ES, Cross TK, Hay N . 1999 Mol. Cell. Biol. 19: 5800–5810

  • Klein B, Zhang XG, Lu ZY, Bataille R . 1995 Blood 85: 863–872

  • Lane HA, Fernandez A, Lamb NJ, Thomas G . 1993 Nature 363: 170–172

  • Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, Pagano M . 2001 Proc. Natl. Acad. Sci. USA 98: 2515–2520

  • Li W, Hyun T, Heller M, Yam A, Flechner L, Pierce JH, Rudikoff S . 2000 Cancer Res. 60: 3909–3915

  • Mahalingam M, Templeton DJ . 1996 Mol. Cell. Biol. 16: 405–413

  • Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H, Sun H . 2001 Curr. Biol. 11: 263–267

  • Medema RH, Kops GJ, Bos JL, Burgering BM . 2000 Nature 404: 782–788

  • Morin PJ . 1999 Bioessays 21: 1021–1030

  • Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR . 2000 Mol. Cell. Biol. 20: 8969–8982

  • Nguyen H, Gitig DM, Koff A . 1999 Mol. Cell. Biol. 19: 1190–1201

  • Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, Anderson KC . 1997 J. Immunol. 159: 2212–2221

  • Parada Y, Banerji L, Glassford J, Lea NC, Collado M, Rivas C, Lewis JL, Gordon MY, Thomas NS, Lam EW . 2001 J. Biol. Chem. 276: 23572–23580

  • Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G . 1998 Science 279: 707–710

  • Puthier D, Bataille R, Amiot M . 1999 Eur. J. Immunol. 29: 3945–3950

  • Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW . 1999 Nat. Genet. 21: 99–102

  • Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB . 1995 Cancer Res. 55: 1982–1988

  • Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W . 1999 Nat. Cell. Biol. 1: 207–214

  • Takuwa N, Fukui Y, Takuwa Y . 1999 Mol. Cell. Biol. 19: 1346–1358

  • Tinhofer I, Marschitz I, Henn T, Egle A, Greil R . 2000 Blood 95: 610–618

  • Toker A, Newton AC . 2000 Cell 103: 185–188

  • Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H . 1999 Curr. Biol. 9: 661–664

  • Tu Y, Gardner A, Lichtenstein A . 2000 Cancer Res. 60: 6763–6770

Download references

Acknowledgements

The authors gratefully acknowledge Christine Guillard for helful discussion of the article and Pr Jean Claude Brouet for providing the OMP2 and RPMI8226 cell lines. Supported by grants from the Comité de Paris of the Ligue Nationale contre le Cancer (Associate Laboratory No. 8).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Didier Bouscary.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pene, F., Claessens, YE., Muller, O. et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21, 6587–6597 (2002). https://doi.org/10.1038/sj.onc.1205923

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205923

Keywords

This article is cited by

Search

Quick links